{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:54:34Z","timestamp":1791078874269,"version":"4.1.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/mjt.0000000000000056","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T16:23:04Z","timestamp":1397492584000},"page":"e749-e756","source":"Crossref","is-referenced-by-count":11,"title":["Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma"],"prefix":"10.1097","volume":"23","author":[{"given":"Malgorzata","family":"Sokolowska-Wojdylo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Florek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Chmielowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Giza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Knopinska-Posluszny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Kulikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Prejzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Romejko-Jarosinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Paszkiewicz-Kozik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Osowiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Rogowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Grzanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Placek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Lugowska-Umer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Nowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210202","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2105\/AJPH.89.8.1240","article-title":"Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality","volume":"89","author":"Weinstock","year":"1999","journal-title":"Am J Public Health"},{"key":"R2-14-20210202","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R3-14-20210202","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European organization for research and treatment of cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"R4-14-20210202","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the international society for cutaneous lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R5-14-20210202","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous T-cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"R6-14-20210202","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"R7-14-20210202","first-page":"276","article-title":"Mycosis fungoides and the S\u00e9zary syndrome","volume":"26","author":"Kim","year":"1999","journal-title":"Semin Oncol"},{"key":"R8-14-20210202","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"88","author":"Diamandidou","year":"1996","journal-title":"Blood"},{"key":"R9-14-20210202","doi-asserted-by":"crossref","first-page":"223","DOI":"10.7326\/0003-4819-93-2-223","article-title":"Prospective staging evaluation of patients with cutaneous T-cell lymphomas","volume":"93","author":"Bunn","year":"1980","journal-title":"Ann Intern Med"},{"key":"R10-14-20210202","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0889-8588(18)30055-8","article-title":"Prognosis and staging of CTCL","volume":"9","author":"Foss","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"R11-14-20210202","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"key":"R13-14-20210202","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.135.1.26","article-title":"Clinical characteristics and long-term outcome of patients with generalized patch or plaque (T2) mycosis fungoides","volume":"135","author":"Kim","year":"1999","journal-title":"Arch Dermatol"},{"key":"R14-14-20210202","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"R15-14-20210202","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0268-960X(03)00004-3","article-title":"Primary cutaneous lymphomas: a review with current treatment options","volume":"17","author":"Querfeld","year":"2003","journal-title":"Blood Rev"},{"key":"R16-14-20210202","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2133.2007.07975.x","article-title":"The optimal use of bexarotene in cutaneous T-cell lymphoma","volume":"157","author":"Gniadecki","year":"2007","journal-title":"Br J Dermatol"},{"key":"R17-14-20210202","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R18-14-20210202","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0360-3016(98)00517-3","article-title":"Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides","volume":"43","author":"Chinn","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R19-14-20210202","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0733-8635(05)70012-7","article-title":"Advances in the management of cutaneous T-cell lymphoma","volume":"16","author":"Sinha","year":"1998","journal-title":"Dermatol Clin"},{"key":"R20-14-20210202","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0733-8635(05)70155-8","article-title":"Emerging therapies in CTCL","volume":"18","author":"Duvic","year":"2000","journal-title":"Clin Dermatol"},{"key":"R21-14-20210202","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides: experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"R22-14-20210202","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0190-9622(96)90282-0","article-title":"Combined modality therapy for cutaneous T-cell lymphoma","volume":"34","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R23-14-20210202","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and S\u00e9zary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"R24-14-20210202","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1991.9.7.1298","article-title":"Mycosis fungoides and S\u00e9zary syndrome: a review of pathogenesis, diagnosis, and therapy","volume":"9","author":"Kuzel","year":"1991","journal-title":"J Clin Oncol"},{"key":"R25-14-20210202","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archderm.1995.01690210033005","article-title":"Prognostic factors in erythrodermic mycosis fungoides and the S\u00e9zary syndrome","volume":"131","author":"Kim","year":"1995","journal-title":"Arch Dermatol"},{"key":"R26-14-20210202","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"R27-14-20210202","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"R28-14-20210202","first-page":"97a","article-title":"Oral bexarotene benefits patients with refractory advanced stage CTCL","volume":"94","author":"Hymes","year":"1999","journal-title":"Blood"},{"key":"R29-14-20210202","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"R30-14-20210202","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2340\/00015555-1359","article-title":"Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland","volume":"92","author":"Vakeva","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"R31-14-20210202","first-page":"1299","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Hematol"},{"key":"R32-14-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2003.11.058","article-title":"Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma","volume":"51","author":"Querfeld","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R33-14-20210202","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjd.12042","article-title":"UK consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma","volume":"168","author":"Scarisbrick","year":"2013","journal-title":"Br J Dermatol"},{"key":"R34-14-20210202","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-010-1553-0","article-title":"Interactions of bexarotene (LGD1069, Targretin) with the coagulation system","volume":"68","author":"Hespel","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"R35-14-20210202","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.ejca.2007.06.015","article-title":"Maintenance therapy in cutaneous T-cell lymphoma: who, what, when?","volume":"43","author":"Dummer","year":"2007","journal-title":"Eur J Cancer"},{"key":"R36-14-20210202","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R37-14-20210202","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2340\/00015555-1114","article-title":"Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma","volume":"91","author":"Ranki","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"R38-14-20210202","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1158\/0008-5472.CAN-04-0366","article-title":"Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue","volume":"65","author":"Karenko","year":"2005","journal-title":"Cancer Res"},{"key":"R39-14-20210202","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/jid.2008.6","article-title":"Clinicopathological characterization and genomic aberrations in subcutaneous panniculitis-like T-cell lymphoma","volume":"128","author":"Hahtola","year":"2008","journal-title":"J Invest Dermatol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0000000000000056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:24:23Z","timestamp":1620962663000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201605000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0000000000000056","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}